Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (338) Arrow Down
Filter Results: (338) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (338)
    • News  (34)
    • Research  (273)
  • Faculty Publications  (228)

Show Results For

  • All HBS Web  (338)
    • News  (34)
    • Research  (273)
  • Faculty Publications  (228)
← Page 12 of 338 Results →
  • November 1991 (Revised August 2005)
  • Case

Whelan Pharmaceuticals: Tax Factors and Global Site Selection

Whelan Pharmaceuticals, a U.S. company with $3 billion in sales, must decide where to manufacture its newest product. In considering possible sites, both foreign and U.S., the firm must identify and make trade-offs between tax, marketing, and manufacturing factors. View Details
Keywords: Globalized Firms and Management; Geographic Location; Cost vs Benefits; Production; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Wilson, G. Peter, and Jane Palley Katz. "Whelan Pharmaceuticals: Tax Factors and Global Site Selection." Harvard Business School Case 192-066, November 1991. (Revised August 2005.)
  • June 2004
  • Case

Aventis SA (B): A Company is Born

By: Joshua D. Margolis and Carin-Isabel Knoop
Supplements the (A) case. View Details
Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (B): A Company is Born." Harvard Business School Case 404-108, June 2004.
  • August 2001
  • Case

Scios, Inc.

By: Regina E. Herzlinger
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States
Citation
Educators
Related
Herzlinger, Regina E. "Scios, Inc." Harvard Business School Case 302-034, August 2001.
  • 01 Sep 2006
  • News

HBS Student Battles ALS

people every year, is not a high priority for either the public or pharmaceutical companies. To stimulate novel treatment ideas and to raise the venture funding needed to get those ideas to market, he launched two organizations. One is... View Details
Keywords: Business Schools & Computer & Management Training; Educational Services; Health, Social Assistance
  • January 2017
  • Case

Medtronic: Making the Big Leap Forward (A)

By: William W. George and Monica Baraldi
In 2014, Medtronic was about to execute a $50 billion acquisition of Ireland-based Covidien. Medtronic CEO Omar Ishrak was committed to building the largest medical technology company in the world while broadening its ability to fulfill its mission of “alleviating... View Details
Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States
Citation
Educators
Purchase
Related
George, William W., and Monica Baraldi. "Medtronic: Making the Big Leap Forward (A)." Harvard Business School Case 317-031, January 2017.
  • April 2002
  • Article

A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany

By: Arthur A. Daemmrich
Keywords: Health; Government and Politics; Pharmaceutical Industry; United States; Germany
Citation
Find at Harvard
Related
Daemmrich, Arthur A. "A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany." Social History of Medicine 15, no. 1 (April 2002): 137–158.
  • August 2008 (Revised May 2009)
  • Background Note

Note on Generic Drugs in the European Union

By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States
Citation
Find at Harvard
Related
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
  • 13 Jul 2020
  • News

Locally Grown

pharmaceutical machinery sector. With the natural beauty of the Rocky Mountains as a backdrop for his career decision, Fenwick-Smith became increasingly interested in climate change and what the business community could do to make a... View Details
Keywords: April White
  • February 2006 (Revised February 2009)
  • Case

AIDS in Brazil

By: Rohit Deshpande and Ricardo Reisen de Pinho
Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra. View Details
Keywords: Price; Government and Politics; Health Care and Treatment; Health Disorders; Rights; Negotiation; Business and Government Relations; Pharmaceutical Industry; Brazil
Citation
Educators
Purchase
Related
Deshpande, Rohit, and Ricardo Reisen de Pinho. "AIDS in Brazil." Harvard Business School Case 506-062, February 2006. (Revised February 2009.)
  • 26 Jul 2016
  • Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Pharmaceutical; Pharmaceutical; Pharmaceutical
  • February 2005 (Revised April 2006)
  • Case

Rx Depot: Importing Drugs from Canada

By: Debora L. Spar
In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot... View Details
Keywords: Courts and Trials; Entrepreneurship; Intellectual Property; Laws and Statutes; Pharmaceutical Industry; Canada; United States
Citation
Find at Harvard
Related
Spar, Debora L., and Adam Day. "Rx Depot: Importing Drugs from Canada." Harvard Business School Case 705-010, February 2005. (Revised April 2006.)
  • 2023
  • Working Paper

Market Exclusivity and Innovation: Evidence From Antibiotics

By: Edward Kong and Olivia Zhao
The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details
Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States
Citation
SSRN
Related
Kong, Edward, and Olivia Zhao. "Market Exclusivity and Innovation: Evidence From Antibiotics." Working Paper, December 2023.
  • March 2023 (Revised March 2024)
  • Case

The Purdue Pharma Bankruptcy: Settling the Opioid Crisis

By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details
Keywords: Regulation; Ethics; Fairness; Insolvency and Bankruptcy; Government Legislation; Courts and Trials; Laws and Statutes; Lawsuits and Litigation; Legal Liability; Crime and Corruption; Negotiation Offer; Negotiation Participants; Negotiation Style; Product Design; Product Development; Brands and Branding; Marketing Strategy; Trust; Government and Politics; Law; Negotiation; Operations; Ownership; Marketing; Social Psychology; Health Care and Treatment; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)
  • May 2010 (Revised June 2010)
  • Supplement

Pfizer: Letter from the Chairman (B)

By: Robert L. Simons and Kathryn Rosenberg
This case continues the story begun in "Pfizer: A Letter from the Chairman" (HBS No. 110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report. View Details
Keywords: Corporate Accountability; Corporate Governance; Business and Shareholder Relations; Value Creation; Decision Choices and Conditions; Annual Reports; Pharmaceutical Industry; United States
Citation
Purchase
Related
Simons, Robert L., and Kathryn Rosenberg. "Pfizer: Letter from the Chairman (B)." Harvard Business School Supplement 110-004, May 2010. (Revised June 2010.)
  • 15 Jan 2018
  • Research & Ideas

A Better Business Model for Fighting Cancer

iPhoto With billions of dollars spent on the development of precision medicine and related cancer research over the last decade, a recent partnership seeks a new way to bring these treatments to patients more quickly: through a better business model. Founded in... View Details
Keywords: by Julia Hanna; Pharmaceutical; Pharmaceutical
  • October 2020
  • Teaching Plan

Merck: COVID-19 Vaccines

By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details
Keywords: Vaccines; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Research and Development; Business Strategy; Pharmaceutical Industry; United States
Citation
Purchase
Related
Shih, Willy C. "Merck: COVID-19 Vaccines." Harvard Business School Teaching Plan 621-067, October 2020.
  • September 2012 (Revised November 2014)
  • Case

Cialis Lifecycle Management: Lilly's BPH Dilemma

By: Elie Ofek and Natalie Kindred
How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new... View Details
Keywords: Product Positioning; Attitudes; Brands and Branding; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Ofek, Elie, and Natalie Kindred. "Cialis Lifecycle Management: Lilly's BPH Dilemma." Harvard Business School Case 513-005, September 2012. (Revised November 2014.)
  • July 2009 (Revised May 2010)
  • Case

Pfizer: Letter from the Chairman (A)

By: Robert L. Simons and Natalie Kindred
This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to... View Details
Keywords: Decision Choices and Conditions; Corporate Accountability; Corporate Governance; Annual Reports; Business and Shareholder Relations; Value Creation; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Simons, Robert L., and Natalie Kindred. "Pfizer: Letter from the Chairman (A)." Harvard Business School Case 110-003, July 2009. (Revised May 2010.)
  • May 2002 (Revised October 2005)
  • Case

Marketing Antidepressants: Prozac and Paxil

By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)
  • March 1993
  • Supplement

Burroughs Wellcome and AZT (C)

By: Willis M. Emmons III
Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details
Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States
Citation
Purchase
Related
Emmons, Willis M., III. "Burroughs Wellcome and AZT (C)." Harvard Business School Supplement 793-115, March 1993.
  • ←
  • 12
  • 13
  • …
  • 16
  • 17
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.